Skip to content
Peptigraph home
Shop Peptides50% off*

Tesamorelin for Joint Pain: What the Evidence Shows

What human and animal studies show about Tesamorelin for joint pain, how strong that evidence is, and what is still unproven.

Medical review pendingGHRH analogUpdated
Strongest evidence
None graded
no study with an outcome for joint pain (PubMed search, 11 Oct 2026)
Human studies
None found
with an outcome for joint pain, in our evidence file (PubMed search, 11 Oct 2026)
Animal studies
None found
with an outcome for joint pain, in our evidence file (PubMed search, 11 Oct 2026)

Evidence for joint pain

None of the study abstracts we summarised for Tesamorelin reported an outcome for joint pain (PubMed search, 11 Oct 2026). Claims that it helps with joint pain are unproven.

How strong is it?

Strongest evidence:No graded study for joint pain (PubMed search, 11 Oct 2026)

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

What joint pain means in the tesamorelin context

MedlinePlus defines joints as the places where bones meet, supported by cartilage, tendons and ligaments.[4]

How many tesamorelin papers mention joint pain

A PubMed title-and-abstract search pairing tesamorelin terms with joint pain terms returned 6 records on 2026-10-29. That is a keyword-match tally for tesamorelin and joint pain, not a count of positive findings.

Calculated from pubmed query (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) AND (arthralgi*[tiab] OR "joint pain"[tiab] OR "knee pain"[tiab] OR "hip pain"[tiab] OR osteoarthr*[tiab] OR cartilage[tiab] OR "joint injury"[tiab] OR "joint damage"[tiab]); date 2026-10-29; count 6. Formula: record count of the PubMed [tiab] query on the date shown, as logged by the literature ledger; no arithmetic

What the retrieved tesamorelin abstracts say about joint pain

A meta-analysis of randomised trials of tesamorelin in HIV-associated lipodystrophy lists arthralgia and myalgia among associated adverse events, so joint pain appears as a possible harm.[5]

A review of tesamorelin for HIV lipodystrophy says most serious adverse events were injection-site reactions or events known with growth hormone therapy, such as arthralgia, headache and peripheral oedema.[6]

The same review reports that tesamorelin was generally well tolerated, with serious adverse events in fewer than 4% of patients over 26 weeks.[6]

Other peptides people research for joint pain

TirzepatideRetatrutideSemaglutideBPC-157WolverineKLOWGLOW
All peptides for joint pain, compared

Common questions

Does Tesamorelin help with joint pain?

None of the studies we summarised for Tesamorelin (PubMed search, 11 Oct 2026) measured an outcome for joint pain. Treat claims that it helps with joint pain as unproven.

Is Tesamorelin approved for joint pain?

Tesamorelin is FDA approved (Egrifta). Which conditions that approval covers is set by the label; use for anything else is off-label.

What is the best peptide for joint pain?

There is no single answer. Our joint pain overview compares each candidate by evidence grade and legal status rather than by popularity.

Is there research on tesamorelin joint pain?

PubMed held 6 records matching the tesamorelin and joint pain search terms when checked on 2026-10-29; a match is not evidence that tesamorelin helps with joint pain.

Calculated from pubmed query (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) AND (arthralgi*[tiab] OR "joint pain"[tiab] OR "knee pain"[tiab] OR "hip pain"[tiab] OR osteoarthr*[tiab] OR cartilage[tiab] OR "joint injury"[tiab] OR "joint damage"[tiab]); date 2026-10-29; count 6. Formula: record count of the PubMed [tiab] query on the date shown, as logged by the literature ledger; no arithmetic

More on Tesamorelin

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1PubMed search: (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) (104 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2PubMed search: (tesamorelin[tiab] OR TH9507[tiab]) AND (pharmacokinetic*[tiab] OR half-life[tiab]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (36 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  4. 4Official web pageOfficial web page · web page
  5. 5Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.Obesity research & clinical practice · 2026PMID 41545261Accessed 11 Oct 2026
  6. 6Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.Drugs · 2011PMID 21668043Accessed 2 Oct 2026

Found an error? Report a correction.